{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T11:39:39Z","timestamp":1769945979558,"version":"3.49.0"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,3,4]],"date-time":"2018-03-04T00:00:00Z","timestamp":1520121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Takeda Development Center Americas, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:p>An open\u2010label, long\u2010term study evaluated safety and tolerability of azilsartan medoxomil\/chlorthalidone (AZL\u2010M\/CLD) vs olmesartan\/hydrochlorothiazide (OLM\/HCTZ) in hypertensive participants with stage 3 chronic kidney disease. Initial therapy was AZL\u2010M\/CLD 20\/12.5\u00a0mg (n\u00a0=\u00a077) or OLM\/HCTZ 20\/12.5\u00a0mg (n\u00a0=\u00a076), but could be up\u2010titrated (AZL\u2010M\/CLD to 40\/25\u00a0mg; OLM\/HCTZ to 40\/25\u00a0mg [US] or 20\/25\u00a0mg [Europe]) with other agents added during weeks 4\u201052. Primary endpoint was proportion of participants with \u2265\u20091 adverse event (AE) through week 52. Baseline demographics were similar. AEs did not differ between groups (88.3%, AZL\u2010M\/CLD vs 76.3%, OLM\/HCTZ;<jats:italic>P<\/jats:italic>\u00a0=\u00a0.058). AZL\u2010M\/CLD showed greater systolic BP reductions after initial dosing (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.037) but not during long\u2010term follow\u2010up (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.588). A greater proportion of participants up\u2010titrated to the highest dose with OLM\/HCTZ (48.7%) vs AZL\u2010M\/CLD (29.9%) (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.021) and were taking additional antihypertensive medications (26.3% vs 16.9%). Both AZL\u2010M\/CLD and OLM\/HCTZ showed similar efficacy and tolerability.<\/jats:p>","DOI":"10.1111\/jch.13230","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T04:56:37Z","timestamp":1520225797000},"page":"694-702","source":"Crossref","is-referenced-by-count":13,"title":["Long\u2010term efficacy and tolerability of azilsartan medoxomil\/chlorthalidone vs olmesartan medoxomil\/hydrochlorothiazide in chronic kidney disease"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-1267","authenticated-orcid":false,"given":"George L.","family":"Bakris","sequence":"first","affiliation":[{"name":"University of Chicago Medicine Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc Deerfield IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Kupfer","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc Deerfield IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"Juhasz","sequence":"additional","affiliation":[{"name":"GE Healthcare Amersham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michie","family":"Hisada","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc Deerfield IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Lloyd","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc Deerfield IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Oparil","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham Birmingham AL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11911-8"},{"key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.20452\/pamw.713","article-title":"Management of hypertension: evidence from the Blood Pressure Lowering Treatment Trialists\u2019 Collaboration and from major clinical trials","volume":"119","author":"Chalmers J","year":"2009","journal-title":"Pol Arch Med Wewn"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4865"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2016.08.001"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.04012"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000839"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000203309.07140.d3"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00418-3"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.425"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.1.308"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.4.354"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2010.00425.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60572-8"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511939"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2008.00015.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000358603"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.188284"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.19.2421"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11811017"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.5.685"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000343453"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32835e2286"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2013-305063"}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjch.13230","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jch.13230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:47:34Z","timestamp":1751449654000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jch.13230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1111\/jch.13230"],"URL":"https:\/\/doi.org\/10.1111\/jch.13230","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"value":"1524-6175","type":"print"},{"value":"1751-7176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,4]]}}}